Test your knowledge

Module 1
Module 2
Module 3
Module 4
Module 5
Module 6
Back to home

Click here for prescribing information and adverse event reporting information (hosted externally).

Module 1
Module 2
Module 3
Module 4
Module 5
Module 6

Module 2: Sleep mechanisms and QUVIVIQ™ action

Introduction

Historically insomnia was considered to be trouble sleeping as a result of underlying conditions or lifestyle‑related behaviour.1 As our learning improves around the science of sleep, new ways of understanding chronic insomnia and the underlying mechanisms behind it are emerging.2,3
QUVIVIQ™ is a treatment for chronic insomnia that works differently to other hypnotics.4,5

Learning objectives

By completing this module, you will increase your awareness and understanding of:

  • The underlying pathophysiological mechanisms of chronic insomnia, including overactive wake signalling
  • The mode of action of QUVIVIQ™ compared with other hypnotics
  • QUVIVIQ™ dosing and administration, sleep hygiene, NICE recommendations and guidance

Multiple-choice questions to test your current knowledge

These questions will help you assess your current knowledge of this topic before you begin to work on the module. Your answers will be marked but will not count towards your final score. You will be asked the same questions again at the end of the module and will be able to download a learning certificate for your records upon completion.

Ready for the next step?

The underlying pathophysiological mechanisms of chronic insomnia

Continue to module
Continue to module

NICE: National Institute for Health and Care Excellence

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.4

This information is intended for UK healthcare professionals.

▼This medicine is subject to additional monitoring.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com

References

  1. Sharpley A L, Attenburrow M E, Cowen P J. Assessment and treatment of insomnia (including a case control of patients with Primary Insomnia). Int J Psychiatry Clin Pract 1997;1(2):107-117
  2. Riemann D, Nissen C et al. The neurobiology, investigation and treatment of chronic insomnia. Lancet Neurol 2015;14(5):547-558
  3. Riemann D, Baglioni C et al. European guideline for the diagnosis and treatment of insomnia. J Res Sleep 2017;26(6):675-700
  4. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
  5. Roch C, Bergamini G et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psycopharmacology 2021;238(10):2693-2708

© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.

UK-DA-00654 | Date of preparation: September 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd
Our Services
PI & AE